AU2014324094B2 - Modified anti-inflammatory proteins and method of use - Google Patents

Modified anti-inflammatory proteins and method of use Download PDF

Info

Publication number
AU2014324094B2
AU2014324094B2 AU2014324094A AU2014324094A AU2014324094B2 AU 2014324094 B2 AU2014324094 B2 AU 2014324094B2 AU 2014324094 A AU2014324094 A AU 2014324094A AU 2014324094 A AU2014324094 A AU 2014324094A AU 2014324094 B2 AU2014324094 B2 AU 2014324094B2
Authority
AU
Australia
Prior art keywords
tmp
protein
modified
disease
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014324094A
Other languages
English (en)
Other versions
AU2014324094A1 (en
Inventor
Andrew Leech
Alex LOUKAS
Darren PICKERING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
James Cook University
Original Assignee
James Cook University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013903588A external-priority patent/AU2013903588A0/en
Application filed by James Cook University filed Critical James Cook University
Priority to AU2014324094A priority Critical patent/AU2014324094B2/en
Publication of AU2014324094A1 publication Critical patent/AU2014324094A1/en
Application granted granted Critical
Publication of AU2014324094B2 publication Critical patent/AU2014324094B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014324094A 2013-09-18 2014-09-18 Modified anti-inflammatory proteins and method of use Active AU2014324094B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014324094A AU2014324094B2 (en) 2013-09-18 2014-09-18 Modified anti-inflammatory proteins and method of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2013903588A AU2013903588A0 (en) 2013-09-18 Modified anti-inflammatory proteins and method of use
AU2013903588 2013-09-18
PCT/AU2014/050240 WO2015039189A1 (en) 2013-09-18 2014-09-18 Modified anti-inflammatory proteins and method of use
AU2014324094A AU2014324094B2 (en) 2013-09-18 2014-09-18 Modified anti-inflammatory proteins and method of use

Publications (2)

Publication Number Publication Date
AU2014324094A1 AU2014324094A1 (en) 2016-05-05
AU2014324094B2 true AU2014324094B2 (en) 2019-03-14

Family

ID=52688012

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014324094A Active AU2014324094B2 (en) 2013-09-18 2014-09-18 Modified anti-inflammatory proteins and method of use

Country Status (8)

Country Link
US (3) US10822395B2 (enExample)
EP (2) EP4509188A3 (enExample)
JP (1) JP2016532456A (enExample)
CN (1) CN105745223A (enExample)
AU (1) AU2014324094B2 (enExample)
CA (1) CA2924220A1 (enExample)
WO (1) WO2015039189A1 (enExample)
ZA (1) ZA201602304B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105745223A (zh) * 2013-09-18 2016-07-06 詹姆斯库克大学 修饰的抗炎蛋白及使用方法
WO2022192955A1 (en) * 2021-03-17 2022-09-22 James Cook University Proteins and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US5284760A (en) 1989-04-03 1994-02-08 Feinstone Stephen M Techniques for producing site-directed mutagenesis of cloned DNA
US6090790A (en) 1989-12-14 2000-07-18 Eriksson; Elof Gene delivery by microneedle injection
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US6054122A (en) 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
DE69233035D1 (de) 1991-12-24 2003-06-05 Harvard College Gezielte punkt-mutagenese von dna
US6756211B1 (en) 1992-05-11 2004-06-29 Corvas International, Inc. Neutropohil inhibitors
US5389514A (en) 1992-08-28 1995-02-14 Fox Chase Cancer Center Method for specifically altering the nucleotide sequence of RNA
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
AUPM672594A0 (en) 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
WO1999047070A1 (en) 1998-03-18 1999-09-23 Wake Forest University Improved implantable biomaterials, compositions and methods for their preparation and uses thereof
JP2000007575A (ja) 1998-06-17 2000-01-11 Fuji Chem Ind Ltd 抗アレルギー剤
AU2001252278A1 (en) 2000-04-05 2001-10-15 Ipf Pharmaceuticals Gmbh Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance
JP4426179B2 (ja) 2000-12-18 2010-03-03 アライバ ファーマシューティカルズ，インコーポレイティド 多機能性プロテアーゼインヒビターおよびそれらの疾患治療における使用
DE10138550A1 (de) 2001-08-06 2003-02-20 Wolfgang E Berdel Verwendung von TIMP-1 als Immunsuppressivum
US7303752B2 (en) 2001-10-17 2007-12-04 The George Washington University Hookworm vaccine
NZ536796A (en) 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
US7928132B2 (en) 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
WO2007005672A2 (en) 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
EP1910417A2 (en) 2005-07-29 2008-04-16 Imperial Innovations Limited Compounds
WO2010048432A1 (en) 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
US9637527B2 (en) * 2012-03-13 2017-05-02 James Cook University Method for treating inflammation with an Ac-TMP-2 protein
US20140274874A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
CN105745223A (zh) 2013-09-18 2016-07-06 詹姆斯库克大学 修饰的抗炎蛋白及使用方法
AU2014324093A1 (en) * 2013-09-18 2016-04-28 James Cook University Anti-inflammatory proteins and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ferreira, I. et al., "Hookworm Excretory/Secretory Products Induce Interleukin-4 (IL-4)+ IL-10+ CD4+ T Cell Responses and Suppress Pathology in a Mouse Model of Colitis", Infection and Immunity. 2013, vol. 81(6), 2104-2111. *
Ruyssers, N. E. et al., "Therapeutic Potential of Helminth Soluble Proteins in TNBS-Induced Colitis in Mice", Inflamm. Bowel. Dis. 2009, vol. 15(4), pages 491-500. *
Zhan, B. et al., "Molecular Cloning and Characterization of Ac-TMP-2, a Tissue Inhibitor of Metalloproteinase Secreted by Adult Ancylostoma caninum", Molecular & Biochemical Parasitology. 2008, vol. 162, pages 142-148. *

Also Published As

Publication number Publication date
CN105745223A (zh) 2016-07-06
CA2924220A1 (en) 2015-03-26
US20160229905A1 (en) 2016-08-11
ZA201602304B (en) 2019-06-26
US12466873B2 (en) 2025-11-11
US11976108B2 (en) 2024-05-07
WO2015039189A1 (en) 2015-03-26
US10822395B2 (en) 2020-11-03
US20240400649A1 (en) 2024-12-05
JP2016532456A (ja) 2016-10-20
US20210061886A1 (en) 2021-03-04
EP4509188A3 (en) 2025-04-02
AU2014324094A1 (en) 2016-05-05
EP3046937A4 (en) 2017-04-26
EP3046937A1 (en) 2016-07-27
EP4509188A2 (en) 2025-02-19

Similar Documents

Publication Publication Date Title
Akdis et al. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens
US12466873B2 (en) Modified anti-inflammatory proteins and method of use
TW202100164A (zh) 用於疫苗遞送之細胞外囊泡
MX2010014575A (es) Nuevos compuestos inmunoadyuvantes basados en flagelina y uso de los mismos.
JP2010516290A5 (enExample)
CN102959082B (zh) 用于治疗自身免疫性和变应性疾病的新组合物和方法
CN110612118A (zh) 用于引起针对hbv的免疫应答的病毒样粒子
WO2013160865A1 (en) Immunotolerizing fusion proteins for treatment of multiple sclerosis
CN110381990A (zh) 马的瘙痒症的治疗
WO2022127825A1 (zh) 针对新型冠状病毒感染的疫苗组合物
CN104411325B (zh) 用于治疗炎症的方法
CN101455846B (zh) 脱乙酰壳聚糖递送系统组装的结核基因疫苗及其制备和应用
JP2023550004A (ja) 融合遺伝子、組換え新型コロナウイルス高効率免疫ｄｎａワクチン、それらの構築方法及び使用
JP2010535504A5 (enExample)
Coria et al. Discovery of protease inhibitors from bacteria as novel adjuvants for oral vaccine formulations
CN104127883B (zh) 以hsp65为表位支架的多t细胞表位结核基因疫苗
JP7239203B2 (ja) ＩｇＥ媒介型アレルギー性疾患治療のための、膜結合型ＩｇＥを標的とするペプチド免疫原及びそれらの製剤
WO2015077442A2 (en) Grass pollen immunogens and methods and uses for immune response modulation
CN118019754A (zh) 诱导pres特异性中和抗体的hbv疫苗
KR20160069204A (ko) 인간 카텔리시딘 ll-37을 포함하는 면역 활성 유도제, 이를 포함한 경구 백신, 및 이를 이용한 면역 활성 유도 방법
ChungCA Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-γ.
WO2012037546A2 (en) A broadly protective protein of brucella and its use in brucellosis vaccine preparation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)